Physician profile
Sofia Horvath
NPI 1619366259
$9,653.33
in general payments reported to CMS, 2019-2025
40 companies · $4,088 in 2025
The $4,088 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $308 · 2021: $1,341 · 2022: $987 · 2023: $1,051 · 2024: $1,509 · 2025: $4,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,467 · Travel and Lodging: $2,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,467.13 |
| Travel and Lodging | $2,180.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,744.69 | 2021-2025 | Evoque |
| Abbott Laboratories | $1,620.30 | 2021-2025 | Triclip, Freestyle Libre |
| Novartis Pharmaceuticals Corporation | $932.12 | 2019-2025 | |
| Pfizer INC. | $553.75 | 2019-2025 | |
| Amgen INC. | $550.16 | 2020-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $497.09 | 2019-2025 | Watchman Flx, General - Therapies |
| E.R. Squibb & Sons, L.L.C. | $437.30 | 2022-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $378.22 | 2019-2025 | Onpattro, Amvuttra |
| Astrazeneca Pharmaceuticals Lp | $344.12 | 2021-2025 | Wainua, Farxiga |
| Janssen Pharmaceuticals, INC | $340.60 | 2020-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $209.87 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $202.39 | 2021-2025 | Prolaris |
| Novo Nordisk INC | $183.76 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Atricure, INC. | $177.77 | 2021 | |
| Amarin Pharma, INC. | $174.64 | 2019-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Horvath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.